Both sirolimus and everolimus, as mTOR inhibitors, have demonstrated anti-proliferative and anti-angiogenic effects in in vitro studies of hemangioma endothelial cells, suggesting their potential role in the treatment of infantile hemangiomas(IHs) (22). The gene discussed is MTOR; the disease is hemangioma.